Le Lézard
Classified in: Health
Subject: RCL

Product Quest Manufacturing LLC Recalls All Nasal Products and Baby Oral Gels Manufactured at Florida Facility Due to Possible Microbial Contamination


HOLLY HILL, Fla., Aug. 28, 2018 /PRNewswire/ -- On August 7, 2018, Product Quest Manufacturing ("Product Quest") announced its voluntary recall of Lot# 173089J of CVS Health 12 Hour Sinus Relief Nasal Mist due to a finding of microbial contamination identified as Pseudomonas aeruginosa.  Out of an abundance of caution, Product Quest has decided to expand the recall to include all lots of nasal products and baby oral gels currently within expiration that were manufactured at the company's Florida facility.  There is no known microbial contamination associated with the nasal products and baby oral gels that are the subject of this expanded recall.  This recall should be carried out to the retail level. 

Risk Statement: Repetitive use of a nasal spray or other nasal product containing a gram-negative pathogen can potentially lead to colonization and subsequent infection which can be life threatening in certain patient populations, such as those with cystic fibrosis or immune-compromised individuals. Similarly, repetitive use of an oral gel product containing a pathogen can potentially lead to colonization and subsequent infection which can be life threatening in certain patient populations, including babies or very young children. To the best of Product Quest's knowledge, the company has not received any reports of adverse events related to this recall to date.

The additional nasal and baby oral gel products included as part of this expanded recall are included in the attached PDF.  The products can be identified by checking the item code, product description, lot #, and expiration date, as included in the attached PDF.

Product Quest is notifying its customers by oral and written communication and is arranging for return/replacement etc. of all recalled products. Consumers/distributors/retailers that have product which is being recalled should stop using the product and return it to the place of purchase.

Consumers with questions regarding this recall can contact Product Quest Manufacturing LLC at 704-939-4342, Monday through Friday from 8 am to 4 pm, EST.  Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these drug products.

Adverse reactions or quality problems experienced with the use of these products may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Company Contact:
Kathryn Weingart, Vice President Quality & Regulatory Affairs
704-939-4342

 

SOURCE Product Quest Manufacturing LLC


These press releases may also interest you

at 20:25
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...

at 20:12
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...

at 19:29
Suffolk DBT is proud to announce the completion of their initial expansion to accommodate the growing need for DBT therapy...

at 18:24
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference. On April 26, 2024, the hearing will commence 11:15 a.m. Members of the public may observe the hearing by videoconference, by...

at 17:55
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....

at 17:43
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...



News published on and distributed by: